Evidence map›Paper›PMID 35339894›Full record

ArticleEBioMedicine2022

Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study.

Yuting Duan, Jingyuan Luo, Lingyun Zhao, Xuan Zhang, Jiangxia Miao, David Moher, Zhaoxiang Bian

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. The worsening divergence of biotechnology: the importance of risk culture.Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yuting DuanChinese EQUATOR Centre, Hong Kong Special Administrative Region of the People's Republic of China; Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China.
Jingyuan LuoChinese EQUATOR Centre, Hong Kong Special Administrative Region of the People's Republic of China; Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China; Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China.
Lingyun ZhaoChinese EQUATOR Centre, Hong Kong Special Administrative Region of the People's Republic of China; Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China.
Xuan ZhangChinese EQUATOR Centre, Hong Kong Special Administrative Region of the People's Republic of China; Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China; Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China.
Jiangxia MiaoSchool of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region of the People's Republic of China.
David MoherCanadian EQUATOR Centre, Ottawa, Canada; Ottawa Methods Center, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada. Electronic address: dmoher@ohri.ca.
Zhaoxiang BianChinese EQUATOR Centre, Hong Kong Special Administrative Region of the People's Republic of China; Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China; Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong Special Administrative Region of the People's Republic of China. Electronic address: bzxiang@hkbu.edu.hk.
Hong Kong Baptist University · HKChinese University of Hong Kong · HKOttawa Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe results and data availability of vaccine trials directly affect the decisions of healthcare providers, the public, and policymakers as to whether the vaccine should be applied. However, the reporting and data sharing level of COVID-19 vaccine studies are not clear.

methodsA cross-sectional study was conducted. A systematic search up to 9 May 2021 in 12 databases and an updated search to 6 July 2021 were conducted in the Cochrane Living Systematic Review and Network Meta-Analysis database to identify COVID-19 vaccine trials. The basic characteristics of included trials were summarized. The reporting level was assessed according to the CONSORT checklist. The data sharing level was assessed by open science practices. Types of incomplete reporting including protocol deviation, lack of primary outcomes clarity, and the omission of harms were analyzed.

findingsFinally, thirty-six COVID-19 vaccine articles reporting on 40 randomized controlled trials were included in this analysis. Based on the CONSORT checklist, the mean reporting score was 29.7 [95% confidence interval 28.7, 30.7]. Thirty-one articles (31/36, 86.1%) had data sharing statements, twenty-five articles (25/36, 69.4%) provided access to the source data. Twenty-seven articles (27/36, 75.0%) had protocol deviation, lack of primary outcomes clarity, or the omission of harms.

interpretationThe reporting and data sharing level of COVID-19 vaccine trials were not optimal. We hope that the reporting and data sharing of future trials will be improved. We recommend establishing a comprehensive, accurate data sharing system for future vaccine trials.

fundingThis work was supported by the National Key R&D Program of China (2019YFC1710400; 2019YFC1710403).

Indexed as

COVID-19COVID-19 VaccinesCross-Sectional StudiesDatabases, FactualHumansInformation DisseminationNetwork Meta-Analysis as TopicSystematic Reviews as TopicCOVID-19 VaccinesCOVID-19Data sharingRandomized controlled trialsReportingVaccine

Identifiers

PMID35339894
PMCPMC8947811
OpenAlexW4220880626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.